Sun Pharmaceutical Industries said it has received approval from US health regulator to market generic Clarinex tablets and Tiazac capsules, used in treating nasal allergies and hypertension, respectively, in the American market.
The tablets are indicated for allergic rhinitis or allergic inflammation of the nasal airways, it said. Allergic Rhinitis occurs when an allergen such as pollen or dust is inhaled by an individual with a sensitised immune system and triggers antibody production.
Clarinex tablets (5 mg) have annual sales of nearly $212 million in the US, it said. In a separate statement, the company said it has received approval from USFDA for generic Tiazac capsules used for treating high blood pressure.
The generic capsules contain Diltiazem Hydrochloride extended release in strength of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg and are therapeutically equivalent to Biovail Corporation's Tiazac capsules, it said.
The capsules are indicated for the treatment of heart diseases including hypertension and also chronic stable angina. Diltiazem Hydrochloride capsules have annual sales of nearly USD 46 million in the US. Shares of Sun Pharma were trading at Rs 2,292 on Bombay Stock Exchange in the late afternoon trade, down 0.56 per cent from its previous close.
Cloud over US FDA inspection
Taro faces ban on products in US market
Orchid gets US nod to sell anti-epileptic drug
Lupin's US arm gets USDFA nod for insomnia tablets
Ranbaxy gets USFDA nod for high BP drug